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Abstract
The lipoprotein encoded by the Francisella tularensis subsp. tularensis locus FTT1103 is essential for virulence; an FTT1103
deletion mutant is defective in uptake and intracellular survival, and mice survive high dose challenges of greater than 10
8
bacteria. This protein has two conserved domains; one is found in a class of virulence proteins called macrophage infectivity
potentiator (Mip) proteins, and the other in oxidoreductase Disulfide Bond formation protein A (DsbA)-related proteins. We
have designated the protein encoded by FTT1103 as FipB for Francisella infectivity potentiator protein B. The locus FTT1102
(fipA), which is upstream of fipB, also has similarity to same conserved Mip domain. Deletion and site-specific mutants of fipA
and fipB were constructed in the Schu S4 strain, and characterized with respect to intracellular replication and in vivo
virulence. A nonpolar fipA mutant demonstrated reduced survival in host cells, but was only slightly attenuated in vivo.
Although FipB protein was present in a fipA mutant, the abundance of the three isoforms of FipB was altered, suggesting
that FipA has a role in post-translational modification of FipB. Similar to many DsbA homologues, FipB contains a cysteine-
any amino acid-any amino acid-cysteine (CXXC) motif. This motif was found to be important for FipB’s role in virulence; a
deletion mutant complemented with a gene encoding a FipB protein in which the first cysteine was changed to an alanine
residue (AXXC) failed to restore intracellular survival or in vivo virulence. Complementation with a gene that encoded a
CXXA containing FipB protein was significantly defective in intracellular growth; however, only slightly attenuated in vivo.
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Introduction
Francisella tularensis subspecies tularensis, also known as type A
Francisella, causes a potentially life-threatening disease called
tularemia. Tularemia can be contracted by the bite of an
arthropod vector, or through inhalation of contaminated particles
or bacteria. Concerns over use of F. tularensis as a biological
weapon have arisen due to its documented use as a bioweapon in
WWII, and reports of the development of weaponized strains that
are resistant to antibiotics and vaccines [1,2]. These concerns have
led to increased interest in defining the mechanisms of virulence,
and immunity as means towards identifying new targets for
therapy and immune protection. There are several other less
virulent subspecies and species of Francisella including the Live
Vaccine Strain (LVS), an attenuated strain of F. tularensis subsp.
holarctica that has been used as a protective vaccine in some parts of
the world, but has never been licensed in the United States [3].
F. tularensis is a facultative intracellular bacterium that can
invade a variety of cell types including macrophages, endothelial
cells, and hepatocytes [4,5,6]. After phagocytosis F. tularensis
resides in a phagosome for up to 4 hours before escaping to the
cytoplasm [7,8,9]. Once in the cytoplasm bacteria replicate,
induce apoptosis or pyroptosis, and are eventually released from
cells. F. tularensis can also reenter the endocytic pathway and reside
in a large membrane-bound compartment that has characteristics
of an autophagocytic vacuole [10]. Thus far only a few loci have
been directly implicated in phagosome survival or escape. Most of
these loci are located on the Francisella pathogenicity island (FPI)
[11,12,13].
Previously we identified a novel non- FPI encoded F. tularensis
lipoprotein, encoded by locus FTT1103, that is defective in
intracellular growth, and essential for virulence in vivo in the highly
pathogenic F. tularensis subsp. tularensis strain Schu S4 [14]. We
have designated the protein encoded by FTT1103 as FipB for
Francisella infectivity potentiator protein B. FipB consists of a
unique combination of conserved domains that are found in a class
of virulence proteins called Mips (macrophage infectivity poten-
tiator) [15], and DsbA oxidoreductases [16]. Mip is a homodi-
meric protein with peptidyl-prolyl cis/trans isomerase (PPIase)
activity. Mip proteins are characterized by two conserved
domains, the Forskolin-binding protein-N (FKBP-N), which is
found at the amino-terminal end of Mip and also FipB, and
FKBP-C, which encodes the PPIase activity. Mip protein was first
identified in Legionella pneumophila as a virulence factor that was
required for optimal intracellular survival and virulence in vivo
[17]. Orthologs have been subsequently identified in several other
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gonorrhoeae [18], and Chlamydia species [19]. A number of other
Gram-negative bacteria have a Mip ortholog at least by
bioinformatic annotation. F. tularensis has a Mip ortholog encoded
by locus FTT1043.
Directly upstream of fipB in the Schu S4 genome is the
FTT1102 locus, which we have designated as fipA. In the original
annotation of the Schu S4 genome fipA was annotated as a
pseudogene. However, proteomic analysis of LVS membrane
fractions identified a peptide encoded by fipA [20]. The FipA
protein is predicted to encode a 96 amino acid lipoprotein, and
differs in only a single amino acid between Schu S4 and LVS. Like
FipB, FipA shares some sequence and structural similarity to the
FKBP-N domain. FipA and FipB are 28% identical to each other
in a 54 amino acid overlap. FipA and FipB are both highly
conserved (.98% identity) in all sequenced isolates and subspecies
of F. tularensis.
Canonical DsbA proteins are periplasmic oxidoreductases that
catalyze disulfide formation in nascent proteins in the periplasmic
space [21]. The active site of DsbA is minimally defined by a
Cysteine- any amino-acid-any amino acid- Cysteine (CXXC)
motif embedded in a thioredoxin-like fold [22]. FipB contains a
CXXC motif, and Straskova et al. have shown that recombinant
protein of the LVS ortholog of FipB has oxidoreductase activity in
vitro [20]. The Schu S4 and LVS FipB orthologs are highly similar;
they differ in seven amino acid residues, which are scattered
throughout the protein. LVS FipB also has 11 extra amino acids
on its carboxyl terminus. There are at least eight families of DsbA-
related proteins in the NCBI conserved domain database (www.
ncbi.nlm.nih.gov/cdd). FipB is most similar to the DsbA_Com1_
like protein family (NCBI; conserved domain cd03023). Com1 is
an outer membrane-associated protein of Coxiella burnetii [16].
Com1-like proteins are present in a number of gram-negative
pathogens, but their roles as virulence factors or as oxidoreduc-
tases have not been fully explored.
The goals of this study were to determine if fipA had roles in
intracellular replication and in vivo virulence, and determine
whether the active site of FipB was involved in this protein’s
essential role in virulence. FipB is a novel protein for several
reasons; it contains the conserved amino-terminal domain of Mip
proteins, and as we show in this paper, it consists of three isoforms,
and it has an accessory protein, FipA, that may function in post-
translational modification. Here we show that FipA is not essential
for virulence, though this mutant does not appear to replicate
intracellularly. We have also shown that in vivo virulence is
dependent on the CXXC motif of FipB. However, only the first
cysteine of the CXXC motif is essential for FipB activity.
Results
FipB is co-transcribed with fipA
Although there are only 20 base pairs separating the open
reading frames of fipA and fipB, it was important for later
complementation studies to confirm that these two genes were
transcribed from the same promoter. We verified that fipA and fipB
are co-transcribed by reverse transcription PCR (RT-PCR)
(Figure 1). As shown in Figure 1, PCR products using primer
pair C/E amplified the intergenic region between fipA and fipB,
and primer pairs A/B, and D/F amplified intragenic fragments of
fipA and fipB, respectively. It is possible that additional loci are co-
transcribed with fipAB. FipAB is flanked by FTT1100, and
predicted pseudogenes, loci FTT1101 and FTT1104. If
FTT1101 consisted of an intact open reading frame, translation
would terminate about 120 base pairs (bps) from the translational
start of fipA. The predicted start of FTT1104 is 287 bps from the
end of fipB. For in-cis complementation of fipAB we included
262 bps upstream of fipA in the plasmid used for constructing the
complemented strains (Table 1, pAQ162, pAQ163, pAQ164).
Since this region of DNA was able to drive expression of fipB in the
complemented strains (Figure 2), it suggests that this region
contains a promoter element.
FipA affects post-translational processing of FipB
When Straskova et al. used various proteomic techniques to
compare the protein profiles of wild-type LVS and an isogenic fipB
(FTL_1096) mutant bacteria only two proteins were absent, FipB
and FipA [20]. This suggested that FipB was required for FipA
protein stability. To investigate the effects of FipA on FipB, and
also the specific contributions of FipA to virulence, nonpolar
mutants in DfipA, DfipB, and DfipAB were constructed. Western
blots with anti-FipB antibody confirmed that the DfipA mutation
was nonpolar (Figure 3). Anti-FipB specific antibody recognized
three bands on Western blots. FipB has been identified as a
glycosylated protein by carbohydrate detection and mass spec-
trometry techniques, so these three isoforms may reflect differences
in glycosylation [23,24]. All three bands disappeared in the DfipB
mutant and also in the DfipAB mutant (data not shown). We noted
that compared to the wild-type strain, the lowest migrating band of
FipB was diminished in the fipA deletion mutant suggesting that
FipA plays some role in FipB post-translation processing or
modification such as glycosylation.
DfipA mutant is defective in intracellular growth
To explore and compare the roles of FipA and FipB in
intracellular growth and virulence J774A.1 cells were infected with
the fipA, fipB,o rfipAB deletion strains, and then assayed for
intracellular growth at several time points using gentamicin
protection assays (Figure 4). All mutants exhibited statistically
significant reduced growth when compared to wild-type Schu S4
at 5 hrs post-infection (p,0.001). The DfipB, and the double
DfipAB mutants had similar phenotypes; in J774A.1 cells the
number of CFUs recovered from these mutants at 24 hrs had
decreased by about two logs from the 5 hr time point, while during
this same time period Schu S4 CFUs had increased by almost 4
Figure 1. fipA and fipB are co-transcribed. RNA was isolated from
wild-type Schu S4, and then converted to cDNA. (A) Overview of
chromosomal region containing fipA and fipB. Short arrows indicate the
location of the PCR primers. The wavy arrow indicates the direction of
transcription. The numbers between the genes indicate the size of the
intergenic region. The hatched boxes (FTT1101 and FTT1104) indicate
predicted pseudogenes. (B) PCR was performed using the indicated
primers (RT-RNA). Controls were: No reverse transcriptase added to the
cDNA synthesis reactions (No RT-RNA), and PCR using Schu S4 DNA as
template and the indicated primers (DNA). Expected sizes of PCR
products were as follows A–B: 314 bps, C–E: 311 bps, and D–F: 392 bps.
doi:10.1371/journal.pone.0024611.g001
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replicate appreciably over this time period, and the number of
recovered CFUs remained stable for up to 48 h. Similar patterns
of defective growth for all of these mutant strains were also
observed in A549 cells (data not shown). The difference in
intracellular growth was not due to an inherent growth defect
because all strains grew similarly in TSB/c and CDM media (data
not shown). FipA and FipB may have independent functions in
intracellular replication, but based on their sequence similarity,
and altered levels of FipB isoforms in the fipA mutant, it seems
likely that their roles in intracellular replication are linked.
DfipA mutant is slightly attenuated in vivo
We have shown here and previously that fipB is essential for in
vivo virulence in mice (Table 2) [14]. To test whether the
intracellular growth defect of the fipA mutant would have any
affect on virulence in vivo, C57BL/6 mice were challenged
intranasally with 2800, 280, or 28 CFUs of DfipA bacteria.
Despite a significant intracellular growth defect in vitro, the fipA
mutant was only mildly attenuated in vivo; as few as 28 CFUs of the
fipA mutant by an intranasal route was lethal, although there was
2–3 day delay in the time to death when compared to mice that
received a challenge dose of 10 CFUs (Table 2).
Figure 2. In cis complementation of DfipAB. Wild-type and mutated
copies of fipB were introduced into DfipAB and then selected for
integration into the blaB locus as described in methods. Western blots
of overnight cultures were prepared and incubated with anti-FipB
specific antibody. Arrow indicates the location of the FipB triplet
isoforms.
doi:10.1371/journal.pone.0024611.g002
Table 1. Bacterial strains and plasmids used in this study.
Name Relevant characteristics Source/Ref
Francisella strains
Schu S4 F. tularensis tularensis, wild-type CDC
BJM1031 Schu S4 DfipB Qin [14]
BJM1068 Schu S4 DfipA This study
BJM1069 Schu S4 DfipA
+B This study
BJM1076 fipA
+B
+ in cis complement of DfipAB This study
BJM1077 fipA
+B C164A in cis complement of DfipAB This study
BJM1078 fipA
+B C167A in cis complement of DfipAB This study
Plasmids
pMP815 Chromosomal integration system vector LoVullo [46]
pGIR463 sacB suicide vector Sullivan [44]
pAQ136 59flanking region of fipA in GIR463 (BM248/BM249) This study
pAQ137 59-and 39flanking regions of fipA in GIR463 (BM250/BM251) This study
pAQ138 59-and 39 flanking regions of fipAB in GIR463 (BM256/BM085) This study
pAQ162 fipA
+fipB
+ in pMP815 This study
pAQ163 fipA
+fipB C164A in pMP815 This study
pAQ164 fipA
+fipB C167A in pMP815 This study
doi:10.1371/journal.pone.0024611.t001
Figure 3. Detection of FipB in the DfipA bacteria. On Western
blots FipB migrates as three bands. In the DfipA mutant the lower band
was diminished. Western blot of bacterial lysates of indicated strains
with anti-FipB antibody; antibody to E. coli GroEL, which cross-reacts
with the Francisella protein, was used as a loading control. Recombi-
nant His-FipB was used to generate the anti-FipB antibody, and serves
as a positive control.
doi:10.1371/journal.pone.0024611.g003
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intracellular replication
The CXXC motif has been shown to be critical for the enzymatic
activity of Escherichia coli DsbA (EcDsbA), and also for substrate
interactions [27,28]. Therefore, we predicted that the CXXC motif
of FipB would also be important for FipB’s role in intracellular
replication, and virulence. To investigate the importance of the
CXXC motif in intracellular growth copies of fipB in which the
cysteines in the CXXC motif had been replaced with alanines,
(C164A and C167A), wereintegrated into the blaB gene ina DfipAB
strain along withthe native promoter and wild-type fipA. Expression
of the mutated genes was confirmed by Western Blots (Figure 2).
The level of FipB in the in-cis complemented strains was similar to
wild-type.
To examine uptakeand the intracellular growth phenotypeof the
CXXC mutants, J774A.1 cells were incubated with the DfipAB or
complemented strains, treated with gentamicin, and then assayed
for growth at 2 and 24 hrs (Figure 5). At 2 hrs post-infection the
Figure 4. DfipA bacteria are defective in intracellular growth. J774A.1 cells were infected at an MOI of 50:1 with the indicated strains of
bacteria as described in materials and methods; cells were thoroughly washed, lysed at the indicated time points, and then diluted and plated to
determine CFU/ml.
doi:10.1371/journal.pone.0024611.g004
Table 2. Survival of fipA, and DfipAB mice after intranasal inoculation.
Strain Relevant genotype # of mice Inoculation dose (CFU)
1 Days to Death
2
Schu S4 4 10 5,5,5,5
BJM1068 DfipA 3 28 7,7,8
BJM1068 DfipA 3 280 6,7,8
BJM1068 DfipA 2 2800 5,6
BJM1069 DfipAB 47 610
7 Survived .30 days
BJM1076 DfipAB-fipA
+B
+ 3 10 6,6,7
BJM1076 DfipAB-fipA
+B
+ 3 100 6,6,6
BJM1076 DfipAB-fipA
+B
+ 3 1000 5,5,5
BJM1076 DfipAB-fipA
+B
+ 44 . 3 610
4 4,4,4,4
BJM1077 DfipAB-fipA
+fipB C164A 4 8.8610
7 Survived .30 days
BJM1078 DfipAB-fipA
+fipB C167A 4 3.4610
7 4,4,4,4
BJM1078 DfipAB-fipA
+fipB C167A 4 3.4610
4 8,8,8,8
BJM1078 DfipAB-fipA
+fipB C167A 4 270 9,9,9,10
BJM1078 DfipAB-fipA
+fipB C167A 4 27 9,10,10, .20 days
1C57/BL6 mice were intranasally challenged with the indicated inoculum dose, which was confirmed by plating the inoculum.
2Indicates the number of days after challenge that mice showed the first signs of irreversible mortality, and were euthanized. Mice were followed for a minimum of 20
days. Similar to the DfipAB mutant, mice similarly challenged with the DfipB mutant survive for more than 30 days without any signs of infection [14].
doi:10.1371/journal.pone.0024611.t002
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bacteria (Figure 5A). A DfipB mutant was also defective in uptake,
but a DfipA mutant had uptake levels similar to wild-type bacteria
(data not shown). Complementation with the C167A or C164A fipB
genes (CXXA or AXXC, respectively) also restored uptake to wild-
type levels. At 24 hrs post-infection complementation of the fipAB
mutantwiththewild-typefipBgenerestoredintracellularreplication
to wild-type levels. The numbers of bacteria recovered from fipAB
mutant, or the strains complemented with CXXA or AXXC genes
were significantly reduced compared to wild-type Schu S4 (p
value,0.00001). However, when the complemented strains were
compared to the DfipAB mutant, the number of CFUs recovered
from the CXXA strain was statistically higher (p value,0.007) than
the DfipAB mutant, while there was no statistical difference between
the AXXC and DfipAB mutants. These results indicated that the
CXXC motif was not required for uptake, but was important for
FipB mediated intracellular replication, however, the C164 amino
acid was more critical for function.
The conserved CXXC motif of FipB is required for in vivo
virulence
In the fipB and fipAB deletion mutants a defect in intracellular
growth correlated with avirulence in mice ([14] & Table 2).
However, this paradigm was not true of the DfipA mutant; despite
a significant intracellular growth defect this mutant still retained
virulence. One difference between DfipA, and DfipAB, was that
between 24 hrs and 48 hrs post-infection the number of viable
DfipA bacteria was stable, while viable DfipAB bacteria had
decreased in number. To test whether the increased number of
Figure 5. Effect of CXXC mutations on uptake and intracellular replication in J774A1. Monolayers of J774A.1 cells were infected with
indicated strains at an MOI of 100:1. The number of intracellular bacteria per well after infection for 2 (A)o r2 4( B) hrs was determined as described in
methods; cells were thoroughly washed, lysed at the indicated time points, and then diluted and plated to determine CFU/ml. Bars represent the
mean 6SD of a representative experiment performed in triplicate. This experiment was repeated two times with similar results. For panel A ‘‘*’’
indicates p,0. 003 compared to Schu S4. For panel B ‘‘*’’ indicates p,0.00001 compared to Schu S4 and ‘‘**’’,0.007 compared to DfipAB.
doi:10.1371/journal.pone.0024611.g005
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compared to the DfipAB strain, translated to a difference in
virulence in vivo, mice were challenged intranasally with decreasing
doses of these various strains (Table 2). Similar to the parental
deletion strain, the AXXC mutant appeared to be avirulent; mice
survived challenges of 8.8610
7 CFUs for more than 30 days. The
CXXA mutant was also attenuated but still retained virulence;
mice challenged with 3.4610
4 CFUs died on day 8. Mice
challenged with 10 CFUs of Schu S4 died on day 5 post-infection,
but few as 27 CFUs of the CXXA, with one exception, also
resulted in a fatal infection on day 9 or 10 post-infection. These
results were consistent with the intracellular replication data (see
Figure 4), and support a critical requirement for the first cysteine
in the CXXC motif of FipB for virulence.
Discussion
FipB is a novel lipoprotein that is required for uptake,
intracellular replication and in vivo virulence of F. tularensis.
Although FipB is novel it has two conserved domains, DsbA_-
Com-1_like (cd03023), and FKBP-N, the amino-terminal domain
of FKBP-type peptidyl prolyl isomerases (cl03173), which are also
known as Mip proteins. To date, this combination of conserved
domains is unique to FipB. FipB is also a lipoprotein, which is
unusual, but not unique for DsbA proteins. Most DsbA are
thought be periplasmic proteins, but a few lipoproteins have been
identified; Neisseria sp., have three DsbA orthologs, and two of these
are lipoproteins [29]. The other novel aspects of FipB include the
presence of three isoforms, which are likely due to post-
translational modification [24], and the presence of an accessory
protein, FipA.
In the Schu S4 genome the FTT1102/fipA locus was annotated
as a pseudogene. However, consistent with the proteomic data
from Straskova et al. [20], which detected the 96 amino acid
peptide corresponding to FipA, we have shown that fipA is indeed
a functional locus. Deletion of fipA resulted in a significant
intracellular growth defect in vitro, though the impact of this gene
loss was not appreciably significant in vivo. It is possible that DfipA
bacteria can replicate in other cell lineages that we have not tested.
Horzempa et al. found that a Schu S4 pyrF mutant, which could
not replicate in human primary macrophages, was able to
replicate in HEK-293 and was virulent in mice [30]. Our results
also suggest that replication in macrophages is not an essential
requirement for virulence.
FipA also has similarity to the FKBP-N domain and is predicted
to be a lipoprotein. One could speculate that fipA and fipB arose as
gene duplications, and then fipA was truncated either in the
process or subsequently. However, this event would have to have
been an early event in the speciation of Francisella, because FipA is
highly conserved among the various species and subspecies of
Francisella, including the more distantly related Francisella philomir-
agia. There has also been considerable sequence divergence
between FipA and FipB, which are only ,28% identical at the
amino acid level. The conserved domain FKBP-N, which is shared
by the two proteins, has previously only been found in the amino-
terminal region of Mip proteins. The crystal structure of LpMip
has been determined [15]. Mip forms a dimer [31], and has its two
conserved domains connected by a very long alpha-helix. The C-
terminal domain of Mip (100–213 amino acids) has PPIase
activity, and amino terminal FKBP-N domain contains the alpha
helical N-term portion of the protein, which is required for
dimerization [15]. The LpMip protein has a complex role in
virulence. It is required for optimal replication in human
macrophages and amoebae [17], migration through an epithelial
barrier [32], and secretion of a phospholipase C-like activity in
culture supernatants [33]. It has been reported that the FKBP-N
or dimerization domain, but not the PPIase domain, is required
for full virulence in Acanthamoeba castellanii [34], suggesting that
dimerization and PPIase domains have separable functions. One
model for FipA function is that it physically interacts or dimerizes
with FipB, which then stabilizes a conformation state that
facilitates post-translational modification or processing. This
model is consistent with our observation that the level of one of
the isoforms of FipB was diminished in a FipB mutant. FipA
dimerization with FipB could also enable a different functional
role for FipB. By proteomic analysis of membrane fractions
Straskova et al. could not detect FipA in a FipB mutant [20], so
FipA may be unstable unless it is able to associate with FipB. The
presence of the FKBP-N dimerization domain in FipB also
suggests that FipB could form a homodimer, which FipA could
potentially regulate or influence. This will require further
investigation. We have observed higher molecular sized complexes
on nonreducing gels, but these complexes were sensitive to
reducing agents, and are likely artifactual interactions between the
cysteines in the active site.
The other conserved region of FipB, the DsbA-Com1-like
domain, is one of several DsbA-related conserved domains. DsbA
was first identified in E. coli, and is the best characterized DsbA
protein both biochemically, and structurally [28]. The conserved
CXXC motif, present in most all DsbA-related conserved
domains, is critical for the oxidoreductase enzymatic activity of
DsbA. In our studies we found that the CXXC motif was critical
for FipB’s role in intracellular survival and in vivo virulence, but
does not appear to be essential for bacterial uptake. In the
intracellular growth assays mutation of two cysteines individually
did not produce identical results; the first cysteine residue was
essential, while the second cysteine mutant had only reduced
function. This finding is consistent with functional characterization
of the CXXC motif of EcDsbA. Based on biochemical and
crystallographic studies, the first cysteine is the nucleophilic
residue that forms a mixed disulfide bond with its substrates.
The second cysteine is hidden within the molecule and less
accessible to solvent. One study that illustrates this difference
examined the oxidation of beta-lactamase, a substrate of EcDsbA.
When a CXXS mutant of EcDsbA was expressed in a wild-type
strain it acted as a dominant negative mutant, which produced a
decrease in the oxidation of beta-lactamase [35]. However,
addition of oxidized glutathione to the media restored beta-
lactamase folding. A SXXC mutant expressed in a wild-type strain
did not exhibit a similar dominant negative phenotype. Based on
this model, our in vivo experiments suggest that the in vivo
environment must be sufficiently oxidizing so that the CXXA FipB
mutant is able to carry its function at a level that is sufficient to
promote virulence.
It is likely that at least part of FipB’s role in virulence is through
the folding of substrates that have critical roles in virulence. In
other pathogenic bacteria DsbA is important for the structure or
function of a number of virulence factors including the biogenesis
of type IV pili in bacteria such as EPEC E. coli, and Pseudomonas
aeruginosa [36,37], the assembly and function of type III secretion
systems in Salmonella typhimurium and Shigella flexneri [38,39,40], and
the Dot/Icm type IV secretion system of L. pneumophila [41].
Identifying FipB substrates will help to define the essential
elements of F. tularensis pathogenicity. However, proteins that
contain a conserved DsbA pfam motif can be quite diverse [42].
With the exception of the active site and a few other conserved
amino acids, many share very little additional sequence similarity.
Therefore, it is likely that the function or structure of some
Francisella Infectivity Potentiator Proteins
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expanded. A number of bacteria have more than one DsbA-
related protein, which also suggests more specialized functions
[42]. Salmonella typhimurium, for example, contains plasmid
encoded protein SrgA, which is a DsbA-related protein that has
a restricted substrate specificity for the plasmid encoded fimbriae
PefA [43]. The usual features of FipB, which include the FKBP-N
domain and some interaction with FipA, suggest that FipB may
also have specialized roles in virulence. The observation that
complementation with CXXA and AXXC alleles was able to
restore uptake supports a specialized role for FipB. FipB may act
as a chaperone, or perhaps more directly mediate this activity.
Indentifying these roles will help to define the essential aspects of
F. tularensis subsp. tularensis virulence.
Materials and Methods
Ethics Statement
All experimental procedures and care of animals was approved
by the University of Virginia’s Institutional Animal Care and Use
Committee. The University’s Animal Welfare Assurance number
is Animal Welfare Assurance #A3245-01, and the vivarium is
accredited by the Association for Assessment Accreditation of
Laboratory Animal Care International.
Bacterial strains, primers, plasmids and culture
Bacterial strains, plasmids, and primers used in these experi-
ments are listed in Tables 1 and 3. Plasmids pGIR463 and
pMP815 were kind gifts of Girija Ramakrishnan and Martin
Pavelka, respectively. E. coli strains were grown in Luria-Bertani
(LB) broth or on LB plates with kanamycin (50 mg/ml) or
ampicillin (100 mg/ml) when required. F. tularensis subsp. tularensis
(type A) Schu S4 was cultured on cysteine supplemented Muller-
Hinton agar (MHA/c) or in cysteine supplemented Trypticase Soy
broth (TSB/c) [44]. For F. tularensis strains 15 mg/ml of kanamycin
was added when appropriate. Studies involving Schu S4 and
derived strains were carried out in an approved Biosafety Level 3
laboratory.
DNA manipulation, cloning, and transformation
DNA was prepared and purified using a commercial kit
(Qiagen, Valencia, CA). Oligonucleotides were synthesized by
Integrated DNA Technologies Inc. (Coralville, IA). Restriction
endonucleases and ligase were purchased from New England
Biolabs (Ipswich, MA). HotStartH Taq (Qiagen) was used for
routine PCR. FastStartH High fidelity PCR system (Roche,
Indianapolis, IN) was used for construction of complementary
and suicide plasmids. All cloning products were verified by DNA
sequencing, which was performed at the University of Virginia
Biomolecular Research Facility. Site direct mutagenesis was
accomplished with a site-directed mutagenesis kit (QuikChangeH,
Agilent Technologies, Cedar Creek, TX) using primer pairs
BM150/BM151 or BM152/153, and pAQ038 as template.
Expression of fipB and mutant genes was verified by Western blot
with rabbit anti-FipB antibody (1:10,000) [14]. DNA transforma-
tion was performed as previously described [44].
Construction of deletion and integration plasmids
To confirm the non-polarity of our deletion mutants we first
complemented these mutations using the Francisella shuttle vector,
pFNLTP [25]. However, in-trans complementation only partially
restored the intracellular growth defect, and these strains also grew
poorly in liquid culture (data not shown). We hypothesized that
over-expression of fipB was deleterious. To circumvent this
problem we integrated the fipAB genes, along with the 262 bps
upstream, into the blaB locus using the plasmid developed by
Lovullo et al. [26]. To construct in-frame deletions of fipA and
fipAB PCR products corresponding to regions upstream and
downstream of fipA or fipAB were produced with primer pairs
BM248/BM249 and BM250/BM251 for fipA and BM256/
BM085 for fipAB (Table 3), and then cloned into the sacB suicide
vector pGIR463 [45]. Plasmids for in cis complementation of fipA,
Table 3. Primers used in this study.
Primer Sequence 59-39 Descript. Restr. Enz.
BM063 TCCATATGCAAGAAATGGCTGCTC F fipB NdeI
BM064 GCGGCCGCTATAAGAAGGATAGGC F fipA NotI
BM066 GGATCCTATCATCATCTTGGCTGAGC R fipB BamHI
BM150 CTTTGATTATCAAGCTATGTACTGTTCTAAGCTTGC F fipB C164A
BM151 GCAAGCTTAGAACAGTACATAGCTTGATAATCAAAG R fipB C164A
BM152 CAATGTATGTACGCTTCTAAGCTTGCTTGCTCC F fipB C167A
BM153 GGAGCAAGCAAGCTTAGAAGCTTACATACATTG R fipB C167A
BM245 AGAAAATATGCGGCCGCGAAATAATAGGAG F fipA NotI
BM208 TCCTCGAGCTTATTTCTTTTGAGCAGCC R fipA XhoI
BM248 GAGCCCTAGGTAGAACAATGGCAACAGG F fipA 59deletion AvrII
BM249 AGGCGGCCGCATTATTTAGTTTCTCCTA R fipA 59deletion NotI
BM250 ATAGATCAGCGGCCGCATGCAATGATTGAATTCC F fipA 39deletion NotI
BM251 ATTAGAGCTCAACACTATCATCATCTTGGCTGAGC R fipA 39deletion XhoI
BM256 CTAAGTCTGCGGCCGCAACAACTAGTACTAGC F fipAB 59deletion NotI
BM085 CTCGAGATTACAGCATTACCAGCTGC F fipAB 39deletion XhoI
BM297 GAGGAATAATAAATGAAATTAACTAAAACTCT F fipA
BM298 TTATTTCTTTTGAGCAGCCAT R fipA
doi:10.1371/journal.pone.0024611.t003
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amplification of the genes using the primers listed in Table 2. Each
amplicon contained 262 bp of the sequence upstream of fipA. PCR
products were ligated into the blaB region of pMP815 [26]. The
resulting plasmids were introduced into the appropriate host
strain, and integrants or subsequent gene deletion mutants were
selected as previously described [14]. The nonpolarity of the fipA
deletion was verified by the detection of FipB on Western blot with
anti-FipB antibody.
Reverse Transcription PCR
Total RNA was isolated from overnight cultures using an
RNeasy Protect mini kit (Qiagen) and treated with DNase I
(Qiagen) to remove contaminating genomic DNA according to the
manufacture’s instructions. First strand cDNA was generated using
SuperScript II Reverse transcriptase (Invitrogen) and random
primers. A parallel transcription reaction without the reverse
transcriptase enzyme was conducted to control for DNA
contamination. Two ml of each reaction was used as a template
for 50 ml PCR reaction.
Uptake and Intracellular growth assays
Assays were performed with murine macrophage J774A.1
(ATCC#TIB-67) cells propagated in high glucose DMEM
supplemented with 10% fetal bovine serum. Cells (2.5610
5/well)
were seeded in 24 well plates, and incubated at 37uC, 5% CO2 for
18 h. Fresh cultures of F. tularensis were diluted in cell culture
medium to reach the desired multiplicity of infection (MOI).
Actual inoculum amounts of bacteria were determined by plating
serial dilutions of the culture inoculum. The plates were
centrifuged at 8006g for 8 min to start the infection, and then
incubated at 37uC for l h. Cells were washed three times in PBS,
and then extracellular bacteria were killed by gentamicin
treatment (50 mg/ml). At the assay endpoint cells were washed,
and then lysed with 0.1% sodium deoxycholate. Lysates were
diluted and plated to determine the number of colony form units
(CFU) in each well. Each experiment had triplicate wells and
repeated a minimum of two times.
Production of FipB antiserum
The DNA sequence of fipB gene was resynthesized with a his-
tag and codons that were biased for E. coli expression (Accession
#JN120022), and then cloned in pET Universal [46]. The
expression of recombinant fipB was induced by the addition of
1 mM IPTG to log phase bacteria. The protein was purified from
induced lysates using Talon beads (Clontech) and eluted with
imidazole according to manufacturer’s recommendations. Purified
protein was dialyzed against PBS, and protein concentration was
determined by BCA assay (Pierce). Purity was verified by SDS-
PAGE and Western blots. Rabbit anti-his-tagged FipB serum was
prepared by Covance Research products Inc (Emeryville, CA).
Mouse anti-FipB serum was made in house.
Mouse virulence studies
For intranasal inoculation 8 to 10-week-old C57BL/6 mice
(Jackson Laboratory) were anesthetized with ketamine-HCl-
xylazine. Twenty microliters of bacteria or PBS was inoculated
into the nares. The actual inoculation doses were confirmed by
viable plate counting. The mice were monitored daily. Mice were
humanely euthanized when death was considered to occur within
24 h. The University of Virginia’s Animal Care and Use
Committee approved all mouse studies.
Statistical analysis
All values were expressed as Mean 6SD and evaluated by using
Student’s unpaired Two-tailed t test with log transformed data,
and assuming unequal variance.
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